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444* Building a CF Center in Gaza − a bridge over troubled water
E. Kerem1, D. Shoseyov1, M. Cohen-Cymberknoh1, S. Armoni1, D. Shanit2.
1Hadassah Medical Center, Pediatrics and CF Center, Jerusalem, Israel; 2The
Peres Center for Peace, Department of Medicine, Healthcare & Bio-medicine
Technology, Tel-Aviv, Israel
The incidence of CF in Israel is 1:5000 births, similar for Jews and Arabs. If a
similar ratio is assumed in the Palestinian population, regardless of consanguineous
factors, a major discrepancy is observed. The actual number of Palestinian patients
is much lower due to under-diagnosis and early death prior to diagnosis. Some
children in the West Bank/Gaza have access to Israeli CF centers, but the majority
are treated only by a few Palestinian physicians specialized in CF. To strengthen
the local independent capacity, we recently trained a physician from Hebron who
is now providing medical care for CF patients in the Red Crescent New Pediatric
Hospital. The situation in Gaza is even worse due to recent political changes. As a
result, CF patients in Gaza are not receiving basic medical care, and many patients
go undiagnosed. Parents of children with CF in Gaza have made a special appeal
to us to receive assistance. The CF Center at the Hadassah Medical Center in
Jerusalem in partnership with the Peres Center for Peace, initiated a development
program that incorporates comprehensive training for Palestinian pediatricians and
auxiliary personnel as well as the setting up of an independent CF center in Gaza
in partnership with a local NGO. This special training program was developed
for medical professionals and includes 2 physicians, a nutritionist, a nurse and
a physiotherapist from Gaza. The 2 physicians and the nutritionist have already
started a 1-year training program and are about to be joined by the nurse and
physiotherapist who will also undergo 3 months practical training. The structure of
the program and the course of training will be presented.
445 Cost analysis of pharmaceutical treatment of adult patients with
cystic ﬁbrosis with regard to severity of lung-function impairment
and nutritional status
C.T. Baltin1, C. Smaczny1, T.O.F. Wagner1. 1Johann Wolfgang Goethe-University,
Pneumology/Allergology, Frankfurt am Main, Germany
Background: While previous studies have indicated that speciﬁc health character-
istics (such as severity of lung-function impairment) can have a major inﬂuence on
medication costs, a quantiﬁcation of these effects has as yet not been prepared for
outpatient CF care.
Objective: The present study quantiﬁes the monetary difference in pharmaceutical
treatment costs for patients with CF between different severity levels of lung-
function impairment as well as different categories of body mass index. Using
statistical analysis, these new ﬁndings aim to increase transparency about utilization
pattern and treatment costs with respect to the patient’s health status.
Method: Based on primary data of daily drug intake for a representative CF
population in the entire year 2007 (n = 124 adult patients attending the CF outpatient
department in Frankfurt, Germany), the effects of lung-function impairment and
BMI were assessed using SPSS for variance tests and ordinary least square-
regression analysis.
Results: Annual medication costs of an adult patient with CF averaged € 17,219
(€ 22,158 including i.v. therapy). Considering FEV1 as a disease severity related
parameter, average medication cost of patients with severe lung function impairment
(FEV1< 40%) were € 21,237, signiﬁcantly higher (p 0.05) than for patients
with normal lung function (FEV1 90%), which averaged € 10,940. OLS-analysis
further indicates an inverse relationship between annual medication costs and BMI
(r = 0.378).
Outlook: Improved transparency around the impact of patient health on CF
medication costs will help to perform cost-beneﬁt assessment and ensure sustainable
medical care for patients with this rare disease.
446 Financial savings following the introduction of a cystic ﬁbrosis
electronic patient record system
N.J. Shaw1, S.P. Conway1, C. Etherington1, M. Denton1, D.G. Peckham1. 1Leeds
Teaching Hospital NHS Trust, Regional Adult Cystic Fibrosis Unit, Leeds, United
Kingdom
Introduction: There is an agreement between the regional Cystic Fibrosis (CF) unit
and the local Primary Care Trusts (PCTs) that high cost drugs such as dornase alfa,
Tobi® and voriconazole which we prescribe via community prescriptions (FP10),
can be cross charged to them. Previously we have found it difﬁcult to match
prescription to patients as data from the Prescription Pricing Authority (PPA) is
anonymised. In 2007 we introduced an electronic patient record systems (EPR)
with e prescribing. We report the impact this system has had on efﬁciency of cross
charging and ﬁnancial savings.
Method: Data was obtained for high cost drugs for the ﬁnancial period 2007–2009.
Drug costs were noted as was the post code of the community pharmacy where
the item was issued. A search by postcode of which patients lived in the vicinity
of the community pharmacy was performed. Patient’s medical records or list of
medication issued electronically via the medication record on EPR were obtained.
Prescriptions were them matched to patients and total cost of the drug crossed
charged to primary care. When there was negative match cross charging could not
occur.
Results: In the ﬁnancial year 2007/8 prior to EPR, £227, and 582 was cross charged
to primary care (63% of the total spend). However in the 2008/9 post EPR, £273,137
was recouped (87% of the total spend).
Conclusion: The introduction of the electronic patient record has improved the
ability to match outpatient prescriptions issued to patients for high cost drugs and
increased cross charging to PCTs. This has had signiﬁcant ﬁnancial beneﬁt for the
Unit.
447 The increased healthcare economic burden associated with
chronic infection with transmissible Pseudomonas aeruginosa
strains in CF
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1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Although chronic infection with transmissible Pseudomonas aeruginosa (Psa) strains
causes increased morbidity, and ultimately mortality in CF patients, the burden
this places on the healthcare economy, of increasing importance in these times of
ﬁnancial austerity, has not been studied. To investigate this further, using logistic
regression we matched (for age, sex, BMI, FEV1, and time since diagnosis) 47 adult
CF patients chronically infected with the commonest UK transmissible Psa strain
(the Liverpool Epidemic Strain, LES) with 47 infected with unique Psa strains and
compared their healthcare costs (inpatient and outpatient care, antibiotic therapy,
and regular prescriptions) over a 5 year period.
Fisher’s exact test, Mann–Whitney’s U test and the chi squared test with Yates
correction were used to analyse the data.
The mean cost per patient per year was higher for LES patients for inpatient care
(£13970 v £4553, p< 0.0001), outpatient attendances (£2635 v £1627, p = 0.02)
and also home and hospital antibiotic therapy (£806 v £181, p< 0.001). Regular
prescription costs were similar in both groups (£847 v £732, p = 0.56). Overall, the
healthcare cost of caring for an adult CF patient with LES chronic infection was
more than twice that for a matched patient with unique Psa strain infection.
CF patients chronically infected with LES place an additional burden on the health-
care economy than that associated with chronic Psa infection. This has implications
for the ﬁnancial modelling currently underway in the UK to adequately resource
CF units, and also underlines the need to prevent infection with transmissible Psa
strains by effective cross infection control strategies.
